Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: A subgroup analysis from the SYNERGY trial
Marc Cohen(Newark Beth Israel Medical Center), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Glenn N. Levine(American College of Cardiology), Philip E. Aylward(Flinders Medical Centre), Neal S. Kleiman(Houston Methodist), Robert M. Califf(Duke University), Harvey D. White(University of Auckland), Karen S. Pieper(Clinical Research Institute), Lan Lan(Second Affiliated Hospital of Zhejiang University), Elliott M. Antman(Brigham and Women's Hospital)
Cited by 19
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k